This company is no longer active
InDex Pharmaceuticals Holding Yönetim
Yönetim kriter kontrolleri 2/4
InDex Pharmaceuticals Holding's CEO is Jenny Sundqvist, appointed in Jan 2023, has a tenure of 1.42 years. total yearly compensation is SEK3.54M, comprised of 64% salary and 36% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK65.60K. The average tenure of the management team and the board of directors is 4.6 years and 8.4 years respectively.
Anahtar bilgiler
Jenny Sundqvist
İcra Kurulu Başkanı
SEK 3.5m
Toplam tazminat
CEO maaş yüzdesi | 64.0% |
CEO görev süresi | 1.4yrs |
CEO sahipliği | 0.02% |
Yönetim ortalama görev süresi | 4.6yrs |
Yönetim Kurulu ortalama görev süresi | 8.4yrs |
Son yönetim güncellemeleri
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -SEK 56m |
Dec 31 2023 | SEK 4m | SEK 2m | -SEK 95m |
Tazminat ve Piyasa: Jenny's total compensation ($USD338.03K) is above average for companies of similar size in the Swedish market ($USD256.68K).
Tazminat ve Kazançlar: Insufficient data to compare Jenny's compensation with company performance.
CEO
Jenny Sundqvist (53 yo)
1.4yrs
Görev süresi
SEK 3,543,000
Tazminat
Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Chief Executive Officer | 1.4yrs | SEK 3.54m | 0.023% SEK 65.6k | |
Deputy CEO & Chief Financial Officer | 7.1yrs | SEK 2.80m | 0.073% SEK 209.8k | |
Chief Scientific Officer | 2.1yrs | Veri yok | 0.0017% SEK 4.9k | |
Head of Regulatory Affairs | 11.4yrs | Veri yok | Veri yok |
4.6yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: INDEX's management team is considered experienced (4.6 years average tenure).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Independent Director | 13.4yrs | SEK 235.00k | 0.081% SEK 232.4k | |
Independent Director | 8.4yrs | SEK 235.00k | 0.077% SEK 219.5k | |
Director | less than a year | Veri yok | Veri yok | |
Member of Advisory Board - North America | no data | Veri yok | Veri yok | |
Member of Advisory Board - Europe | no data | Veri yok | Veri yok | |
Independent Chairman | 13.4yrs | SEK 500.00k | 0.14% SEK 406.6k | |
Member of Advisory Board - Europe | no data | Veri yok | Veri yok | |
Chairman of Advisory Board - Europe | 2yrs | Veri yok | Veri yok | |
Member of Advisory Board - Europe | no data | Veri yok | Veri yok | |
Member of Advisory Board - Europe | no data | Veri yok | Veri yok | |
Member of Advisory Board - Europe | no data | Veri yok | Veri yok | |
Member of Advisory Board - North America | no data | Veri yok | Veri yok |
8.4yrs
Ortalama Görev Süresi
70yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: INDEX's board of directors are considered experienced (8.4 years average tenure).